Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough has published phase II trial results which found treatment with its drug Caelyx, in combination with carboplatin, to be highly effective in advanced ovarian cancer which had been previously treated.
Subscribe to our email newsletter
The overall tumor response rate of 63% shown by Caelyx plus platinum combination was associated with a complete response rate of 38%, a median survival of 32 months and a median progression-free survival of 9.4 months.
Standard therapy for recurrent ovarian cancer is a regimen containing paclitaxel and carboplatin. However, neurotoxicity is a significant cumulative side effect of taxane containing chemotherapy regimens and therefore there is a need for a non-taxane option.
The results of this trial shows that the combination of Caelyx and carboplatin are similar to standard therapy and offers lower neurotoxicity rates than seen in earlier studies of taxane and platinum combinations.
An international trial with Caelyx is underway to expand on these findings and to identify the optimal treatment regimen for patients with relapsed ovarian cancer, said Schering-Plough.